Keyword Analysis & Research: tesaro

Keyword Analysis


Keyword CPC PCC Volume Score Length of keyword
tesaro1.110.84775876

Keyword Research: People who searched tesaro also searched

Keyword CPC PCC Volume Score
tesaro0.90.1945073
tesarovitch1.510.9673183
tesaro gsk1.990.7174558
tesa roller1.140.8634814
tesaro stock1.310.8566580
tessarol1.40.1309840
tesarolle0.820.250652
tesarova1.590.2340046
tesaro italia0.521803117
tesaro stock price1.050.1575497
tesaro kit construct0.530.9642030

Search Results related to tesaro on Search Engine

  • GSK reaches agreement to acquire TESARO, an oncology focused

    gsk.com

    https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-to-acquire-tesaro-an-oncology-focused-biopharmaceutical-company/

    WEBDec 3, 2018 · Issued: London UK. GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) today announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 …

    DA: 78 PA: 54 MOZ Rank: 12

  • GSK completes acquisition of TESARO, an oncology focused

    gsk.com

    https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-tesaro-an-oncology-focused-biopharmaceutical-company/

    WEBJan 22, 2019 · GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has successfully completed the acquisition of TESARO, Inc. an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of …

    DA: 26 PA: 93 MOZ Rank: 9

  • Tesaro - Wikipedia

    wikipedia.org

    https://en.wikipedia.org/wiki/Tesaro

    WEBTesaro Inc. is a pharmaceutical company based in Waltham, Massachusetts. They focus on drug development for cancer . History. Tesaro was founded in 2010. [1] . The company's first commercial product, Varubi, was approved by the FDA in October 2015. [2] . As of 2016, the company had 286 full-time employees, 59 of whom had a PhD or MD. [3] .

    DA: 21 PA: 30 MOZ Rank: 96

  • Agreement to acquire TESARO | GSK

    gsk.com

    https://www.gsk.com/en-gb/investors/corporate-actions/agreement-to-acquire-tesaro/

    WEBOn 3 December 2018 we announced our agreement to acquire TESARO, an oncology-focused company based in the US for approximately $5.1bn. The proposed transaction will significantly strengthen our pharmaceutical business, accelerating the build of our pipeline and commercial capability in oncology.

    DA: 53 PA: 78 MOZ Rank: 100

  • Thorny path: A replay of how Tesaro got its $5.1B …

    fiercepharma.com

    https://www.fiercepharma.com/pharma/checkered-path-a-replay-how-tesaro-got-its-5-1-billion-glaxosmithkline-buyout

    WEBDec 17, 2018 · Pharma. Thorny path: A replay of how Tesaro got its $5.1B GlaxoSmithKline buyout. By Angus Liu Dec 17, 2018 12:36pm. M&A ovarian cancer PARP inhibitors Clovis Oncology. Tesaro's shares...

    DA: 40 PA: 9 MOZ Rank: 28

  • TESARO, Inc. | LinkedIn

    linkedin.com

    https://www.linkedin.com/company/tesaro

    WEBTESARO, Inc. | 31,186 followers on LinkedIn. TESARO is an oncology-focused business within GlaxoSmithKline (GSK) with a clear mission that drives all of our actions.

    DA: 62 PA: 53 MOZ Rank: 11

  • GSK closes $5.1bn Tesaro acquisition - Pharmaceutical …

    pharmaceutical-technology.com

    https://www.pharmaceutical-technology.com/news/gsk-closes-tesaro-deal/

    WEBJan 23, 2019 · GlaxoSmithKline ( GSK) has completed its acquisition of US-based biopharmaceutical company Tesaro for an aggregate cash consideration of $5.1bn. An agreement for the acquisition was signed in December last year. The deal boosts GSK’s pharmaceutical business by supporting its oncology pipeline.

    DA: 14 PA: 51 MOZ Rank: 54

  • GSK slides after buying cancer firm Tesaro for hefty $5.1 billion

    reuters.com

    https://www.reuters.com/article/idUSKBN1O218B/

    WEBDec 3, 2018 · LONDON (Reuters) - GlaxoSmithKline has agreed to buy U.S. cancer specialist Tesaro for $5.1 billion, a costly investment to rebuild the pharmaceuticals business by new Chief Executive Emma...

    DA: 22 PA: 35 MOZ Rank: 63

  • GSK to Acquire PARP Inhibitor Developer Tesaro for $5.1B

    genengnews.com

    https://www.genengnews.com/news/gsk-to-acquire-parp-inhibitor-developer-tesaro-for-5-1b/

    WEBDec 3, 2018 · GlaxoSmithKline (GSK) said today it agreed to acquire Tesaro for approximately $5.1 billion, in a deal the buyer said would “significantly” accelerate the development of its pipeline and...

    DA: 44 PA: 67 MOZ Rank: 98

  • GSK buys Tesaro in $5.1B takeover deal | BioPharma Dive

    biopharmadive.com

    https://www.biopharmadive.com/news/gsk-buys-tesaro-in-51b-takeover-deal/543438/

    WEBDec 3, 2018 · Dive Brief: GlaxoSmithKline will acquire Tesaro, a Massachusetts-based oncology firm, for $5.1 billion, the two companies announced Monday. The takeover will give the British drugmaker control of Zejula, Tesaro’s PARP inhibitor and leading therapeutic asset.

    DA: 10 PA: 51 MOZ Rank: 20